Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
4.6
Journals
Pharmaceuticals
Special Issues
Potential Therapeutic Target for Atherosclerosis
share announcement

Potential Therapeutic Target for Atherosclerosis

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 3451

Special Issue Editor

Dr. Catherine Martel

E-Mail Website
Guest Editor
1. Montreal Heart Institute, Montréal, QC H1T1C8, Canada
2. Department of Medicine, Faculty of Medicine, Université de Montréal, Montréal, QC H3C 3J7, Canada
Interests: atherosclerosis; extracellular vesicles; inflammation; lymphatics

Special Issue Information

Dear Colleagues,

 

Atherosclerosis, the main underlying cause of cardiovascular disease (CVD), is characterized by sustained inflammation and failed inflammation resolution. Despite the great advances in pharmaceutical therapy, CVD remains the leading cause of death worldwide. A deeper understanding of the mechanisms that promote atherosclerotic lesion onset and progression may identify novel therapeutic targets for the prevention and treatment of the disease. The aim of the present Special Issue is to attract high-quality articles that focus on potential innovative therapeutic strategies for the immune, cellular, and molecular mechanisms of atherosclerosis. We welcome opinions, brief reports, communications, and research articles, as well as reviews.

Dr. Catherine Martel
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • atherosclerosis
  • monocytes
  • macrophages
  • cholesterol
  • inflammation
  • treatment
  • prevention

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

63 pages, 2647 KiB  
Review
Alterations of HDL’s to piHDL’s Proteome in Patients with Chronic Inflammatory Diseases, and HDL-Targeted Therapies
by Veronika Vyletelová, Mária Nováková and Ľudmila Pašková
Pharmaceuticals 2022, 15(10), 1278; https://doi.org/10.3390/ph15101278 - 18 Oct 2022
Cited by 10 | Viewed by 3153
Abstract
Chronic inflammatory diseases, such as rheumatoid arthritis, steatohepatitis, periodontitis, chronic kidney disease, and others are associated with an increased risk of atherosclerotic cardiovascular disease, which persists even after accounting for traditional cardiac risk factors. The common factor linking these diseases to accelerated atherosclerosis [...] Read more.
Chronic inflammatory diseases, such as rheumatoid arthritis, steatohepatitis, periodontitis, chronic kidney disease, and others are associated with an increased risk of atherosclerotic cardiovascular disease, which persists even after accounting for traditional cardiac risk factors. The common factor linking these diseases to accelerated atherosclerosis is chronic systemic low-grade inflammation triggering changes in lipoprotein structure and metabolism. HDL, an independent marker of cardiovascular risk, is a lipoprotein particle with numerous important anti-atherogenic properties. Besides the essential role in reverse cholesterol transport, HDL possesses antioxidative, anti-inflammatory, antiapoptotic, and antithrombotic properties. Inflammation and inflammation-associated pathologies can cause modifications in HDL’s proteome and lipidome, transforming HDL from atheroprotective into a pro-atherosclerotic lipoprotein. Therefore, a simple increase in HDL concentration in patients with inflammatory diseases has not led to the desired anti-atherogenic outcome. In this review, the functions of individual protein components of HDL, rendering them either anti-inflammatory or pro-inflammatory are described in detail. Alterations of HDL proteome (such as replacing atheroprotective proteins by pro-inflammatory proteins, or posttranslational modifications) in patients with chronic inflammatory diseases and their impact on cardiovascular health are discussed. Finally, molecular, and clinical aspects of HDL-targeted therapies, including those used in therapeutical practice, drugs in clinical trials, and experimental drugs are comprehensively summarised. Full article
(This article belongs to the Special Issue Potential Therapeutic Target for Atherosclerosis)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop